Dopamine, serotonin, and norepinephrine are essential for neurotransmission in the mammalian system. These three neurotransmitters have been the focus of considerable research because the modulation of their production and their interaction at monoamine receptors has profound effects upon a multitude of pharmacological outcomes. Our interest has focused on neurotransmitter reuptake mechanisms in a search for medications for cocaine abuse. Herein we describe the synthesis and biological evaluation of an array of 2-aminopentanophenones. This array has yielded selective inhibitors of the dopamine and norepinephrine transporters with little effect upon serotonin trafficking. A subset of compounds had no significant affinity at 5HT 1A , 5HT 1B , 5HT 1C , D 1 , D 2 , or D 3 receptors. The lead compound, racemic 1-(4-methylphenyl)-2pyrrolidin-1-yl-pentan-1-one 4a, was resolved into its enantiomers and the S isomer was found to be the most biologically active enantiomer. Among the most potent of these DAT/NET selective compounds are the 1-(3,4-dichlorophenyl)-(4u) and the 1-naphthyl-(4t) 2-pyrrolidin-1-yl-pentan-1-one analogues.
Introduction
The endogenous monoamines, dopamine (DA), serotonin, and norepinephrine (NE) are essential for neurotransmission in the mammalian system. These three neurotransmitters, their biological receptors, and their reuptake mechanisms are the focus of considerable research because modulation of their production and their interaction at monoamine receptors has profound effects upon a multitude of pharmacological outcomes. [1] [2] [3] [4] [5] [6] [7] [8] Dopamine, serotonin, and norepinephrine are released into the synapse where their concentrations are regulated, at least in part, by reuptake proteins located in the presynaptic membrane. 9, 10 These reuptake mechanisms have been termed the dopamine transporter (DAT), serotonin transporter (SERT), and the norepinephrine transporter (NET). The DAT is the target of numerous therapeutic agents, such as Ritalin (methylphenidate), Adderral (amphetamine), Wellbutrin, and Zyban (bupropion). Our interest has focused on the DAT in a search for medications for cocaine abuse 2,11-14 because cocaine's reinforcing and stimulant properties have long been associated with its propensity to bind to and inhibit monoamine transport systems, especially the DAT. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Our work has concentrated on the design of compounds that inhibit all three monoamine uptake systems with different degrees of potency and selectivity. In the search for a new class of compounds that may provide a different access to agents that target the transport systems, our attention was drawn to bupropion ( Figure 1 ), a compound marketed as an antidepressant (Wellbutrin) as well as a smokingcessation drug (Zyban). Bupropion is a 2-substituted aminopropiophenone 25, 26 that has been explored extensively. Interestingly, and of relevance to the work which we describe later, the enantiomers of bupropion may not differ in their ability to inhibit biogenic amines. 27 Bupropion is structurally closely related to a 2-substituted aminopentanophenone, pyrovalerone ( Figure 1 ).
In 1992, Lancelot reported that pyrovalerone inhibits the DAT and the NET and is a weak inhibitor of the SERT. 28 Its synthesis was first reported by Heffe in 1964. 29 Stille 30 and Holliday 31 confirmed its stimulant activity in animals and humans in 1963. In 1971, pyrovalerone was demonstrated to reduce symptoms of chronic fatigue in humans. 32 Later studies in rat hearts revealed that it inhibits NE uptake and effects the release of NE from storage or functional pools. 25, 33 In 1993, Vaugeois et al. 34 reported that pyrovalerone stimulated the locomotor activity in mice (2 mg/kg) for up to 1 h and that this duration of action paralleled the time course of its DAT occupancy. Notwithstanding this early clinical interest, the literature reveals little SAR on pyrovalerone. Lancelot et al. 28 reported the exchange of the phenyl ring for a thiophenyl ring. This exchange resulted in analogues of similar potency for both the inhibition of DA and NE uptake. Furthermore, an increase in size of the nitrogen containing ring from a five-membered pyrrolidine to a sixmembered piperidine caused a substantial loss in binding potency in all uptake mechanisms. These researchers also reported that their analogues inhibited both DA and NE uptakes but were less potent at inhibition of the SERT, a finding very similar to that now reported for the analogues of the present study. Since then, one pharmacological study has appeared 34 in which pyrovalerone was shown to occupy striatal sites labeled with GBR12783 and manifest an increase in locomotor activity. However, there are no further reports concerning SAR or biological enantioselectivity of pyrovalerone or analogues. Consequently, there is little directly relevant SAR to guide the dibenzoyl-D-tartrate and (2R)-pyrovalerone dibenzoyl-D-tartrate salts, respectively. After four recrystallizations, the triplet at 0.73 ppm was no longer visible. The absence of the triplet attests to the diastereomeric purity of the compound, and this can be assumed to be >95% de on the basis of the limits of sensitivity of the NMR experiment. It is noteworthy that the purified dibenzoyl-D-tartaric and L-tartaric acid diastereomeric salts of 4b and 4c are enantiomers, and both resonate at δ 0.71 for ω-methyl. Assignment of the absolute optical configuration of this diastereomer was confirmed by X-ray structural analysis as (2R) (optical rotation was [R] 20 D +59.6°(c 1.06, EtOH)). Upon treatment with aqueous Na 2 CO 3 and extraction into Et 2 O, then treatment with HCl, this diastereomeric salt gave (2R)pyrovalerone 4c.
(2S)-Isomer 4b was then obtained from the enriched mother liquors by reaction with dibenzoyl-L-tartaric acid, recrystallization of the diastereomeric salts (optical rotation was [R] 20 D -61.1°(c 1.07, EtOH)), and liberation of 4b upon treatment with aqueous sodium carbonate. The chiral center does not epimerize under these conditions. The enantiomeric purity of 4b and 4c can be anticipated to be >95% ee, that is, the same as the diastereomeric purity of the precursor dibenzoyl tartrate salts. Enantiomeric purity was confirmed by HPLC chiral resolution using a Chiralpak AD column. Each isomer was thus confirmed to be >99% pure (ee > 98%).
R, -Unsaturated ketones 5a and 5b were obtained (Scheme 2) by dehydrobromination of 3a and 3u with Li 2 CO 3 /LiBr in DMF. Reaction with pyrrolidine then gave 6a and 6b respectively. Compounds 7a and 7b were accessible via the Mannich reaction of 3a and 3b with paraformaldehyde and pyrrolidine hydrochloride. Compound 3u was also used to provide 9f (reaction with butylamine) and 9g (reaction with piperidine). Compounds 9a and 9b were prepared (Scheme 3) by reaction of the appropriate R-bromoketones with pyrrolidine. Compounds 9c-e were prepared from 2-pyrrolidinyl 8 29 by alkylation with propargyl bromide in the presence of sodium amide or by alkylation with allyl bromide followed by treatment with aqueous sodium hydroxide. Reduction of 4a with LiAlH 4 gave 9h and 9j as a mixture of diastereomers, which were separated by flash column chromatography. All amines were converted to their HCl salts and recrystallized from EtOH/Et 2 O for biological assay with the exception of 4v, which was isolated as its HBr salt.
Biology
The ligand affinities (K i , nM) for inhibition of dopamine, serotonin, and norepinephrine transporters were determined in competition studies with [ 125 I]RTI 55. Inhibition of monoamine uptake (IC 50 , nM) was evaluated in competition with [ 3 H]dopamine, [ 3 H]serotonin, and [ 3 H]norepinephrine and is presented in Tables 1 and 2 . In general, the analogues of 1-(4-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one provide numerous examples of compounds that are potent inhibitors of the dopamine transporter and of dopamine reuptake. These compounds also inhibit NE reuptake with some potency but are generally inactive at the SERT and for serotonin reuptake inhibition. One notable exception to this selectivity is the naphthyl analogue 4t, which binds to all three transporters and inhibits reuptake at the nanomolar potency range. The lead compound, racemic pyrovalerone 4a, has been demonstrated here to be biologically enantioselective because the DAT inhibitory potency of the racemic mixture of 4a resides entirely with the 2S-enantiomer, 4b (DAT K i ) 18.1 nM; DA IC 50 ) 16.3 nM). Of these DAT/NET compounds, the most potent is 3,4-dichlorophenyl substituted 4u, with DAT K i ) 11.5 nM and NET K i ) 37.8 nM. At this time, it is unclear whether the inherent lipophilicity of both 4t and 4u is primarily responsible for their inhibitory potency. This question is currently being explored further.
Discussion
The lead compound for these studies was racemic 1-(4methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (pyrovalerone) 4a (Table 1 ). In our assays, this compound proved a potent inhibitor of both RTI 55 binding (K i ) 21.4 nM, about 20-fold more potent than cocaine, as measured in the same assay) and dopamine (DA) uptake (IC 50 ) 52 nM, about 9-fold more potent than cocaine). Its potency of RTI 55 inhibition of the NET (K i ) 195 nM) as well as norepinephrine (NE) uptake (IC 50 ) 28.3 nM) was also marked. It was found to be more potent than cocaine in this assay by about 11-fold and 13-fold, respectively. The discrepancy between the inhibition of RTI 55 binding at the NET compared with the inhibition of NE uptake was seen throughout this series of compounds. This discrepancy was first reported by Eshleman et al. in 1999. 36 They also noted that such differences were less evident in the case of DATs and SERTs. They suggested that this difference was likely a consequence of the ligand binding site on the NET being less closely linked to the sites of drug interactions with the substrate and (NE) translocation than is the case for the DAT and the SERT.
Compound 4a was relatively inert at the SERT, with potency in the micromolar range. Therefore, racemic 4a was potent at the DAT and NET and selective against the SERT. Compound 4a exists as two enantiomers; only racemic 4a has been evaluated previously. The critical importance of absolute stereochemistry on biological function is well established. It is particularly relevant that both amphetamine (1-phenyl-2-aminopropane) and cathinone (1-phenyl-2-aminopropane-1-one) are biologically enantioselective with respect to their inhibition of DATs and NETs. 37, 38 Indeed, the S-enantiomers are the eutomers in both cases. These two compounds bear strong structural similarities to the 1-aryl-2-pyrrolidin-1-yl-pentan-1-one analogues of this study, and therefore it was likely that their binding to, and thus inhibition of, these transporters may likewise be similar. However, the structural similarity of the 1-aryl-2pyrrolidin-1-yl-pentan-1-ones to the 2 -carbomethoxy-3R-aryl-8-azabicyclo[3.2.1]octane (tropane) class of DAT inhibitors is less clear. It is therefore interesting to note a comparison that utilized Dreiding models of WIN 35, 428 (Figure 1 ) with enantiomers 2S-4b and 2R-4c (Scheme 4). The pyrrolidine nitrogens and the centroids of the aromatic rings were held coincident. In this rudimentary analysis, the propyl side chain in the 2S configuration overlapped with the C2--carbomethoxy of the tropane. However, the 2R-configured compound had the propyl chain in a position similar to that of the 2R-carbomethoxy Scheme 4. Resolution of 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one 4a a of the tropane. It has been well established that the 2Rcarbomethoxy tropane analogues are less potent at the DAT than their 2 -carbomethoxy counterparts. On this basis, we had postulated that 2S-4b might be the active enantiomer at the DAT. As shown in Table 1 , enantiopure (2R-4c) is a poor inhibitor of RTI 55 binding at both DAT (K i ) 1330 nM) and SERT (K i > 10 µM). In contrast, enantiopure (2S-4b) was quite potent at DAT (K i ) 18.1 nM) and selective (SERT: K i > 2 µM). It was interesting that this relative potency of the 2S-4b enantiomer extended to the NET. Here, the 2R-4c enantiomer was effectively inert at NET inhibition and NE uptake, and the potency of racemic 4a resided exclusively in the 2S-4b enantiomer (NET: K i ) 109 nM; NE uptake: IC 50 ) 11.3 nM).
It is evident from the biological data (Table 1 ) that the inhibitory activities of these compounds cannot be easily correlated with varying electron density on the aromatic ring, with lipophilicity, or molecular refractivity. To this extent, this family of 1-aryl-2-pyrrolidin-1-yl-pentan-1-one analogues differs from other monoamine uptake inhibitors, such as the 8-oxa-, 8-thia-, and 8-aza-bicyclo[3.2.1]octanes 11, 12, 39, 40 and methylphenidate analogues, 41, 42 where structure-activity relationships (SAR) are more easily discerned. Notwithstanding, certain relationships were evident among these analogues. Most clear was the fact that these 1-aryl-2-pyrrolidin-1-yl-pentan-1-one analogues were generally poor inhibitors of the SERT. Only two compounds (4t and 4u) manifested SERT K i values of <200 nM. The naphthyl analogue 4t inhibited SERTs with modest potency (K i ) 33.1 nM), and the high lipophilicity of this compound (c log P ) 4.77) may be partially responsible for this potency. However, the lipophilic dichlorophenyl analogue 4u (c log P ) 5.01) manifested a lesser SERT potency (K i ) 199 nM). Therefore, lipophilicity was likely not the only factor that determined the potency for 4t. Within the family of analogues evaluated, the 3,4-dichlorophenyl analogue 4u was the most potent at DAT (K i ) 11.5 nM), followed by the 4-methyphenyl analogue 4a. At NET, only 4q (K i ) 69.8 nM) and 4u (K i ) 37.8 nM) were potent inhibitors of RTI 55 binding, although many compounds manifested substantial inhibition of NE uptake (4a IC 50 ) 28.3; 4b IC 50 ) 11.3 nM; 4d IC 50 ) 56 nM; 4f IC 50 ) 83 nM; 4g IC 50 ) 46.5 nM; 4h IC 50 ) 81 nM; 4j IC 50 ) 12.4 nM; 4k IC 50 ) 86.7 nM; 4n IC 50 ) 22.8 nM; 4q IC 50 ) 19.3 nM; 4r IC 50 ) 19.7 nM; 4s IC 50 ) 9.4 nM; 4t IC 50 ) 11.7 nM; 4u IC 50 ) 21 nM; 4v IC 50 ) 7.6 nM; 4x IC 50 ) 93 nM; 9a IC 50 ) 18.5 nM; 9b IC 50 ) 18.0 nM; 9c IC 50 ) 88 nM; 9d IC 50 ) 24.9 nM).
It was particularly interesting that of those evaluated, the catechol analogue 4v was one of the most potent inhibitors of NE uptake (IC 50 ) 7.6 nM). Protection as dimethoxy compound 4w completely obliterated the potency at all three monoamine transporters. The contrast between the inhibition of the RTI 55 binding at the NET and the inhibition of NE uptake is quite marked in the comparison of the disubstituted compounds 4u (3,4-dichloro substitution) and 4v (catechol moiety). In the former, the ratio of inhibition of NET binding to NE inhibition is about 2-fold, whereas in the latter this ratio is closer to 30fold. The significance of this is unclear, although this may again imply that the ligand binding site on the NET is only loosely associated with the site that effects NE translocation. 36 The position of the methyl substituent on the aromatic ring influenced NE uptake potency in an opposite sense to its influence on DAT inhibition, although DA uptake inhibition was similar. Although the 3-methyl analogue 4s manifested a NE uptake IC 50 ) 9.4 nM, the 2-methyl 4r and 4-methyl 4a manifested IC 50 values of 19.7 and 28.3 nM, respectively. A comparison of 4-methyl 4a (DAT: K i ) 21.4 nM; NET: K i ) 195 nM), 2-methyl 4r (DAT: K i ) 59.7 nM; NET: K i ) 425 nM), and 3-methyl 4s (DAT: K i ) 51 nM; NET: K i ) 216 nM) 1-aryl-2-pyrrolidin-1-yl-pentan-1-ones showed that 4-methyl 4a was at least twice as potent as 2-methyl 4r and 3-methyl 4s at DATs. 3-Methyl 4s was about equipotent to 4-methyl 4a at the NET, although 2-methyl 4r remained about half as potent at the NET compared with that of 4a. The most DAT versus NET selective compound in this series was the 4-acetamido derivative 4o with DAT K i ) 30.2 nM and NET K i ) 4 µM.
The search for medications for cocaine abuse has centered, primarily, on two approaches. The first is the design of compounds that can act as cocaine substitutes and that manifest, in contrast to cocaine, slow onset rates and long durations of action. 11, [43] [44] [45] The second approach has been to seek cocaine antagonists. 13 These compounds would manifest high potency for the inhibition of cocaine binding to the DAT and little or no effect on DA uptake (i.e., DA trafficking). This has been the focus of numerous studies, and Deutsch and Schweri 46 have described the discrimination ratio (DR) as a guiding measure of potential cocaine antagonism. They defined the DR as the IC 50 of DA uptake inhibition/K i for the inhibition of DA uptake by the test compound. They pointed out that a DR < 10 is of little significance, owing to the differences in conditions of each assay protocol. By this standard, none of the compounds here showed a DR > 5, and therefore none can be regarded as cocaine antagonists. Their use as potential medications for cocaine addiction may be derived from the onset and duration of action extensions, and these factors are currently under investigation.
Of note, the biaryl compounds 4x-z lacked impressive potency at all sites. This, again, is contrary to the effects of such substitution in the bicyclo[3.2.1]octane series in both the 8-aza 47 and 8-oxa series, as we shall report elsewhere. 48 Table 2 presents an array of compounds that explored the displacement of the pyrrolidine ring along the butyl chain (6a, b), the introduction of different C2 side chains (9a,b) as well as the introduction of side chain unsaturation (9c-e), and the effects of opening the pyrrolidine ring (9f) as well as expanding it to the six-membered piperidine (9g). Finally, the reduction of the ketone to obtain both isomers (9h and 9j) is presented. The stereochemistry of these two diastereomers has not been determined yet. However, neither isomer shows any potency at the DAT, SERT, and NET. A comparison of 6a with 4a and 6b with 4u showed that essentially all inhibitory potency at all three transporters was lost when the pyrrolidine ring was moved one carbon along the chain. The nature of the pyrrolidine itself appears to be important because when it was opened (9f) or expanded (9g), the inhibitory potency was much reduced compared with that of parent compound 4u. Lancelot et al. 28 had published a similar finding in their evaluation of 2-amino-1-(2-thienyl)-1-pentanones. Reduction of the ketone 4a to yield the diastereomeric alcohols 9h and 9j provided totally inactive compounds. Modification of the alkyl chain of 4a proved interesting. Although a terminal acetylene (9e) resulted in a substantial loss of potency at DATs, SERTs, and NETs, the allyl compounds 9c and 9d retained potency at DATs. 3,4-Dichloro compound 9d (DAT: K i ) 39.9 nM) was again the more potent of the two, although NET potency declined substantially (K i ) 509 nM) compared with that of comparative compound 4u (K i ) 37.8 nM). Of these chain altered compounds, isobutyl analogue 9b proved most interesting with DAT K i ) 13.7 nM but DA uptake IC 50 ) 5.9 nM. This compares with data for 4a (DAT K i ) 21.4 and DA uptake IC 50 ) 52 nM). Thus, the introduction of a branching methyl in the side chain has served to increase DA inhibition about 10-fold over the parent compound 4a. The possible significance of this is not clear at this time.
The biological selectivity within this class of compounds proved striking. Thirteen compounds (4b, f, k-m, o, p, r-t, y, 6a, and 6b) were evaluated for inhibition of 5HT 1A , 5HT 1B , 5HT 1C , D 1 , D 2 , and D 3 receptors. The compounds were essentially inactive (IC 50 > 10 µM) in these assays. Two compounds (4o, which was a selective DAT inhibitor and 4t, which had similar potency at the DAT and SERT) were selected for evaluation of locomotor activity. Both manifested a timeand dose-dependent stimulation of locomotor activity (ED 50 ) 0.21 mg/kg and 2.2 mg/kg, respectively) with a duration of action of >8 h.
Conclusion
A family of 38 analogues of lead compound 1-(4-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (pyrovalerone) has been prepared. The biological activity at dopamine, serotonin, and norepinephrine transporters has been determined. This family has yielded compounds that provide selective inhibitors of the dopamine and norepinephrine transporters with little effect upon serotonin trafficking. Furthermore, a subset of compounds selected for evaluation of their effect upon serotonin and dopamine receptors has shown them to be inactive at these sites.
Lead compound 4a has been demonstrated to be biologically enantioselective, and it remains to be determined whether this enantioselectivity extends to other members of this family of compounds. Two compounds, 4o and 4t, manifested a timeand dose-dependent stimulation of locomotor activity with a duration of action of >8 h.
The inhibitory potency, the neurotransmitter selectivity profile, and the inactivity at selected receptor sites of 4k and 4o have encouraged us to enter behavioral pharmacological evaluation in rat drug discrimination studies, and in vivo studies are currently ongoing.
Experimental Section
NMR spectra were recorded on a JEOL 300 NMR spectrometer (300.53 MHz for 1 H and 75.58 MHz for 13 C) with tetramethylsilane (TMS) as the internal standard and DMSO-d 6 as the solvent, with the exception of compounds 2 and 3, which were measured in CDCl 3 . Optical rotations were measured on a Jasco P1010 polarimeter at room temperature. HPLC and MS data were obtained on an Agilent series 1100 LC/MSD system. Melting points are uncorrected and were measured on a Mel-Temp melting-point apparatus. Thin-layer chromatography (TLC) was carried out on Baker Si 250F plates. Visualization was accomplished with iodine vapor, UV exposure, and treatment with phosphomolybdic acid (PMA). Flash chromatography was carried out on Baker silica gel 40 µM (silica gel). All reactions were conducted under an atmosphere of dry nitrogen. Elemental analyses were performed by Atlantic Microlab, Norcross, GA. Chemicals obtained from commercial sources were used as received. Room temperature is 22 ( 2°C. Yields have not been optimized.
General Procedure A. Preparation of Intermediate Ketones 2. Ketones 2 were prepared (except where noted) by the alkylation of the analogous commercially available nitrile compounds, followed by acidic hydrolysis. The nitrile (10 mmol) was added in several portions, over 0.5 h, to a solution of the n-BuMgCl (12 mmol) in toluene (20 mL). The reactions were monitored by TLC and heated where necessary. Generally, after 2 h of stirring at room temperature, the reaction was complete. The reaction mixture was poured onto ice, and concentrated H 2 SO 4 (2 mL) was added. Hydrolysis of the intermediate imine usually occurred at room temperature after several minutes. However, for some substrates, heating was necessary to effect this transformation. The organics were extracted into Et 2 O, dried (MgSO 4 ), filtered, and reduced in vacuo to an oil.
General Procedure B. Preparation of Intermediate r-Bromoketones 3. Compounds 3 were prepared by the R-bromination of ketones 2. The ketone (as a solution in Et 2 O, or CH 2 Cl 2 (for less soluble substrates)) was cooled in an ice bath, and anhydrous AlCl 3 was added to the solution (1-5 mol %). Bromine (approximately 0.1 mol equiv) was added to the solution all at once. Typically, after 10 min the solution changed from light orange to colorless. (If this change did not occur at 0°C, then the mixture was warmed to room temperature.) The remaining bromine (0.9 mol equiv) was then added to the solution in a dropwise manner over 5 min. The solution was neutralized (aqueous NaHCO 3 ), separated, dried (MgSO 4 ), filtered, and reduced to a light-colored oil in vacuo. Yields were quantitative, and the crude materials were sufficiently pure ( 1 H NMR) for use in the subsequent step.
General Procedure C. 1-Aryl-2-pyrrolidin-1-yl-pentan-1-ones (4). Compounds 4 were prepared employing general procedure C except where noted. R-Bromoketone 3 (10 mmol) was dissolved in Et 2 O (10 mL) (EtOH is a suitable alternative solvent) and cooled in an ice bath. Pyrrolidine (22 mmol) was added all at once. The mixture became orange, and an oil was observed to separate from the solution. The ether was removed, and the free base was dissolved in EtOH (50 mL) and heated to 70°C. Dibenzoyl-D-tartaric acid (12.7 g, 35.5 mmol) in hot ethanol (150 mL) was added all at once to the pale-yellow solution of the free base. The resulting colorless solution was refluxed for 1 min and cooled, and the solvent was removed in vacuo. The residue was dissolved in CH 2 Cl 2 (530 mL), and hexane (700 mL) was added with swirling. After 3 days, the resulting crystalline solid (9.1 g) was collected by filtration. 1 H NMR (CDCl 3 ) showed a diastereomeric excess (de) of 70-75%. Three consecutive recrystallizations from CH 2 Cl 2 /hexane (300/400 mL) gave a single diastereoisomer (6.1 g, 61%); mp 100-120°C. 1 The salt was dissolved in 20% aqueous Na 2 CO 3 and extracted into Et 2 O. The Et 2 O layer was collected, dried, and filtered. Ethereal 2 M HCl was added to this solution to provide a white solid that was recrystallized from EtOH/Et 2 O to give pure (1R)-1-(4-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one hydrochloride (4c). The physical properties of this compound were identical to those of the racemic material 4a.
The residues from the recrystallization of the dibenzoyl-D-tartaric acid (1R)-1-(4-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one were combined, and the free base was liberated with 20% aqueous Na 2 -CO 3 . The ethereal extracts were washed once with 20% aqueous Na 2 CO 3 , dried (MgSO 4 ), filtered, and reduced in vacuo to an oil (5.2 g, 21 mmol). This oil was dissolved in hot EtOH (50 mL), and a solution of dibenzoyl-L-tartaric acid (7.5 g, 21 mmol) in hot EtOH (100 mL) was added with swirling. The mixture was refluxed for 1 min and cooled, and the solvent was removed in vacuo. Four recrystallizations, as described above, gave a single diastereoisomer (5.4 g, 50%). X-ray structural analysis confirmed the diastereomeric salt of dibenzoyl-L-tartaric acid (1S)-1-(4-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one.
[R] 20 D -61.1°(c 1.07, EtOH).
The hydrochloride salt of (1S)-1-(4-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one 4b was then prepared as described above for (1R)-1-(4-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one.
The enantiomeric purities of 4b and 4c were confirmed by chiral HPLC (Chiralpak AD, 0. 1-(4-hydroxymethylphenyl)pentan-1-one (2j) 35 and converted to 4j as described in general procedure C (79% yield); mp 186-187°C dec. 1 1-(4-Hydroxyphenyl)-2-pyrrolidin-1-yl-pentan-1 -one Hydrochloride (4k). 1-(4-Methoxyphenyl)-2-pyrrolidin-1-yl-pentan-1-one (4m) (9.00 g, 30.3 mmol) was freed from its hydrochloride salt by basification to pH 8-9 with 20% aqueous Na 2 CO 3 and extraction into CH 2 Cl 2 . The free base was dissolved in CH 2 Cl 2 (50 mL) and cooled to -78°C. BBr 3 (90 mL, 1.0 M solution in CH 2 Cl 2 , 90 mmol) was added to the solution over 0.5 h. The mixture was stirred for another hour before warming gradually to room temperature. The gummy mixture, which became difficult to stir, was quenched after 2 h with saturated aqueous NaHCO 3 , and the neutral organics were extracted into CH 2 Cl 2 . A white solid precipitated from the aqueous layer and was collected on a frit (2.8 g). This material was dissolved in Et 2 O and treated with 2 M ethereal HCl. The solid obtained was collected by filtration and then recrystallized from ethanol to give pure 1-(4-hydroxyphenyl)-2-pyrrolidin-1-yl-pentan-1-one as its hydrochloride (4k) (2.9 g, 34%); mp 235°C dec. 1 
1-(4-Nitrophenyl)-2-pyrrolidin-1-yl-pentan-1-one Hydrochloride (4l).
A 50% w/w aqueous solution of H 2 O 2 (7 mL, 0.12 mol) was added to CH 2 Cl 2 (50 mL) that had been cooled in an ice bath. Trifluoroacetic anhydride (23 mL, 0.14 mol) was added slowly via syringe. The solution was then warmed to room temperature. N-[4-(2-Pyrrolidin-1-ylpentanoyl)phenyl]acetamide hydrochloride (4o) (4.5 g, 18 mmol) was added over 20 min, and the mixture was heated to reflux for 1 h. The solution was cooled and then quenched cautiously with aqueous Na 2 SO 3 (100 mL of a 1.6 M solution, 0.16 mol). The organics were separated and extracted into Et 2 O and then back-extracted into 1 M aqueous HCl. The acidic extracts were basified with 20% aqueous Na 2 CO 3 to pH 8-9 and extracted into Et 2 O. The organic extracts were dried (MgSO 4 ), filtered, and then treated with 2 M ethereal HCl. The resulting white precipitate was collected on a frit, dissolved in water, and then freeze dried to give pure 1-(4-nitrophenyl)-2-pyrrolidin-1-yl-pentan-1-one hydrochloride (4l) (290 mg, 5%); mp 189°C dec. 1 06 (d, 2H) , 5.13 (t, 1H), 3.96 (s, 3H), 2.2-2.05 (m, 2H), 1.65-1.35 (m, 2H), 1.00 (t, 3H) was prepared (general procedure B) from 2n 35 and converted to 4n as described in general procedure C (77% yield); mp 202°C dec. 1 N-[4-(2-Pyrrolidin-1-yl-pentanoyl) phenyl]acetamide Hydrochloride (4o). N-(4-Pentanoylphenyl)acetamide (2o) prepared in 60% yield by Friedel-Crafts acylation of acetanilide in CS 2 and purified by recrystallization from hot MeOH: 1 yellow mixture was warmed slowly to room temperature and stirred for 3 h. The yellow solution was hydrolyzed cautiously with aqueous Na 2 CO 3 (20% solution) until the pH was 8 and then water (50 mL) was added, and the solution was allowed to stand overnight. Neutral organics were extracted from the mixture by the separation of the CH 2 Cl 2 layer, which was then discarded. The aqueous layer was acidified to pH 3 with 1 M HCl, most of the water was removed by rotary evaporation, and the remaining volume of ca. 10 mL was allowed to cool in the refrigerator. After 3 days, a white solid separated from the solution and was collected by filtration. Recrystallization (EtOH/Et 2 O) afforded pure 1-(3,4-dihydroxyphenyl)-2-pyrrolidin-1-yl-pentan-1-one (4v) as its hydrobromide, an off-white solid (0.60 g, 44%); mp 181-182°C. 1 1-(4-Furan-2-ylphenyl)-2-pyrrolidin-1-yl-pentan-1-one Hydrochloride (4x). This compound was prepared using a procedure analogous to that described later for the preparation of 4z, except that commercially available 2-tributylstannyl furan was employed as a starting material, and chromatography was not performed on the crude free base. The crude hydrochloride was recrystallized from hot EtOH to give pure 4x as a colorless crystalline solid: (59% yield); mp 236°C dec. 1 2-Pyrrolidin-1-yl-1-(4-thiophen-2-yl-phenyl)pentan-1-one Hydrochloride (4y). This compound was prepared using a procedure analogous to that described later for the preparation of 4z, except that commercially available 2-tributylstannyl thiophene was employed as a starting material, and chromatography was not performed on the crude free base. The crude hydrochloride was readily obtained by the treatment of the crude free base with 2 M ethereal HCl. Recrystallization from hot EtOH gave pure 4v as a colorless crystalline solid (61% yield); mp 220°C dec. 1 1-(4-N-Methylpyrrolephenyl)-2-pyrrolidin-1-yl-pentan-1one Hydrochloride (4z). To a cooled (-78°C) solution of N-methylpyrrole (1.14 g, 14 mmol) in THF (10 mL), t BuLi (9.1 mL of a 1.7 M solution in pentane, 15 mmol) was added dropwise. The mixture was then warmed to room temperature for 2 h and then cooled to -78°C. Chlorotributylstannane (5.0 g, 15 mmol) was added to the mixture dropwise. On completion of addition, the mixture was warmed to room temperature and stirred for 1 h. The mixture was filtered and reduced to an oil in vacuo. This oil (crude 2-tributylstannyl-(N-methylpyrrole)) was added to a solution of 2-pyrrolidin-1-yl-1-(4-bromophenyl)-pentan-1-one (that had been freed from its hydrochloride 4f by treatment with 20% aqueous Na 2 CO 3 and extraction into Et 2 O) in dioxane (30 mL). The resulting solution was degassed by purging with N 2 . [Pd(PPh 3 ) 4 ] (264 mg, 0.22 mmol) was added, and the mixture was heated to 95-100°C (oil bath temperature) for a period of 10 h. The solvent was removed in vacuo. The pure free base was obtained by column chromatography (5% MeOH/CH 2 Cl 2 ) as a yellow oil. The hydrochloride was prepared by treatment with 2 M ethereal HCl. Lyophilization of an aqueous solution of the salt afforded 1-(4-N-methylpyrrolephenyl)-2-pyrrolidin-1-yl-pentan-1-one hydrochloride as pale-green solid 4z (1.4 g, 36%); mp 185°C. 1 1-(4-Methylphenyl)pent-2-en-1-one (5a). This compound was prepared as described below for 5b, employing 2-bromo-1-(4methylphenyl)pentan-1-one (3a) as the starting material (82% yield). 1 1-(3,4-Dichlorophenyl) pent-2-en-1-one (5b). 2-Bromo-1-(3,4dichlorophenyl) pentan-1-one (3u) (3.36 g, 10.9 mmol) was dissolved in DMF (60 mL). Li 2 CO 3 (1.28 g, 17 mmol) and LiBr (0.99 g, 11.5 mmol) were added to the solution, which was then heated with stirring to 110-120°C (oil bath temperature) for 1.5 h. The mixture was diluted with H 2 O (100 mL), and the organics were extracted into EtOAc (3 × 50 mL). The ethyl acetate layer was collected and washed with saturated brine (2 × 50 mL), dried (MgSO 4 ), filtered, and reduced to an oil in vacuo. Flash column chromatography (1% EtOAc/hexane to 2.5% EtOAc/hexane) furnished pure 5b as a colorless solid (1.5 g, 60%). 1 1-(3,4-Dichlorophenyl) 1-(4-Methylphenyl)-3-pyrrolidin-1-yl-pentan-1-one Hydrochloride (6a). This compound was prepared from 1-(4-methylphenyl)-2-en-1-one (5a) using the same procedure as that described for 6b; mp 97°C dec. 1 H NMR δ 11.1-10.9 (br, 1H), 7.94 (d, 2H), 7.38 (d, 2H), 3.9-3.75 (br, 1H), 3.7-3.6 (m, 1H), 3.6-3.3 (m, 3H), 3.15-2.95 (br, m, 2H), 1.96 (s, 3H), 2.0-1.8 (br, m, 5H), 1.8-1.6 (m, 1H), 0.88 (t, 3H); 13 1-(3,4-Dichlorophenyl)-2-pyrrolidin-1-yl-methylpentan-1one Hydrochloride (7b). 2-Bromo-1-(3,4-dichlorophenyl)pentan-1-one (3u) (3.5 g, 15 mmol), pyrrolidine.HCl (2.4 g, 23 mmol), and paraformaldehyde (1.35 g, 45 mmol) were taken up in i PrOH (25 mL) containing concentrated HCl (0.2 mL). The mixture was brought to reflux for 16 h. The solvent was removed by rotary evaporation, and the residue was separated between 1 M aqueous HCl and Et 2 O. The aqueous extracts were basified with 20% aqueous Na 2 CO 3 to pH 8-9, and the organics were extracted into Et 2 O. The organics were dried (MgSO 4 ), filtered, and reduced to an oil in vacuo. Column chromatography (10% MeOH/CH 2 Cl 2 ) gave the pure free base. Reaction with 2 M ethereal HCl and filtration of the resulting white precipitate provided 1-(3,4-dichlorophenyl)-2-pyrrolidin-1-yl-methylpentan-1-one hydrochloride (7b) (0.61 g, 12%); mp 168°C dec; 1 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-methylpentan-1-one Hydrochloride (7a). This compound was prepared from 1-(2methylphenyl)pentan-1-one (3.5 g, 20 mmol) using the same method described for 7b with the following modifications. No chromatography was performed. The hydrochloride salt of the crude free base was isolated after extraction of the crude reaction mixture into 1 M aqueous HCl and back extraction (with 20% aqueous Na 2 CO 3 ) into Et 2 O, followed by acidification with 2 M HCl in Et 2 O. The product was recrystallized from EtOH/Et 2 O to give pure crystalline 1-(4-methylphenyl)-2-pyrrolidin-1-yl-methylpentan-1-one hydrochloride (7a) (2.6 g, 44%); mp 176°C dec. 1 96 (d, 6H ). 4-Methyl-2-pyrrolidin-1-yl-1-(4methylphenyl)pentan-1-one hydrochloride (9b) was then prepared as described in general procedure C (68% yield); mp 218°C dec;
